Janus kinase inhibitors in autoimmune bullous diseases

Dawei Huang; Yuexin Zhang; Luyang Kong; Jiajing Lu; Yuling Shi

doi:10.3389/fimmu.2023.1220887

Janus kinase inhibitors in autoimmune bullous diseases

Front Immunol. 2023 Jul 10:14:1220887. doi: 10.3389/fimmu.2023.1220887. eCollection 2023.

Authors

Dawei Huang^{1

2}, Yuexin Zhang^{1

2}, Luyang Kong^{1

2}, Jiajing Lu^{1

2}, Yuling Shi^{1

2}

Affiliations

¹ Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
² Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.

Abstract

Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins. Currently, the preferred treatment for AIBD involves the use of glucocorticoids or traditional immunosuppressants. Additionally, the utilization of biological agents such as rituximab, omalizumab, and dupilumab is on the rise. However, effectively managing AIBD remains a challenge. The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway has been implicated in various inflammatory diseases. In recent years, a range of drugs known as JAK inhibitors, which target this pathway, have been developed. Several studies have explored the efficacy and safety of JAK inhibitors for treating AIBD. Consequently, this review begins by examining the role of the JAK/STAT pathway in AIBD, summarizing the application of different JAK inhibitors in AIBD treatment, and emphasizing the importance of disease management in treating AIBD with JAK inhibitors. Furthermore, it highlights the need for a better understanding of the JAK/STAT pathway's role in AIBD, as well as the effectiveness and safety of JAK inhibitors for treating this disease.

Keywords: JAK-STAT signaling pathway; Janus kinase inhibitor; autoimmune bullous disease; pemphigoid; pemphigus.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Autoimmune Diseases* / drug therapy
Humans
Janus Kinase Inhibitors* / pharmacology
Janus Kinase Inhibitors* / therapeutic use
Janus Kinases / metabolism
STAT Transcription Factors / metabolism
Signal Transduction
Skin Diseases, Vesiculobullous*

Substances

Janus Kinase Inhibitors
Janus Kinases
STAT Transcription Factors

Grants and funding

This work was sponsored by grants from National Natural Science Foundation of China (No. 82073429, 82273510, 82003335), Innovation Program of Shanghai Municipal Education Commission (No.2019-01-07-00-07-E00046), Clinical Research Plan of SHDC (No. SHDC2020CR1014B) and Program of Shanghai Academic Research Leader (No. 20XD1403300).